Reaction
Infectious Mononucleosis reporting signals
As of the last recalculation, Infectious Mononucleosis appears in 2,226 FAERS reports alongside 31 co-occurring drug terms. The strongest observed disproportionality signal is ISOTRETINOIN (PRR 18.3).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Isotretinoin | 93 | 18.3 | 18.3 |
| Cyclobenzaprine Hydrochloride | 14 | 14.7 | 14.7 |
| Ivacaftor | 11 | 13.0 | 13.0 |
| Human Immunoglobulin G | 27 | 12.4 | 12.4 |
| Canakinumab | 13 | 11.3 | 11.3 |
| Infliximab | 165 | 7.6 | 7.6 |
| Infliximab-Dyyb | 21 | 6.8 | 6.8 |
| Tofacitinib Citrate | 9 | 6.4 | 6.4 |
| Atomoxetine Hydrochloride | 16 | 6.3 | 6.3 |
| Adrenalinum | 27 | 6.1 | 6.1 |
| Etonogestrel And Ethinyl Estradiol | 14 | 5.9 | 5.9 |
| Asfotase Alfa | 6 | 5.6 | 5.6 |
| Omalizumab | 41 | 4.6 | 4.6 |
| Vedolizumab | 41 | 4.5 | 4.5 |
| Dornase Alfa | 9 | 4.3 | 4.3 |
| Vilazodone Hydrochloride | 4 | 4.1 | 4.1 |
| Sodium Oxybate | 27 | 3.9 | 3.9 |
| Ravulizumab | 5 | 3.5 | 3.5 |
| Certolizumab Pegol | 41 | 3.3 | 3.3 |
| Lumacaftor And Ivacaftor | 3 | 3.3 | 3.3 |
| Natalizumab | 59 | 3.1 | 3.1 |
| Drospirenone And Ethinyl Estradiol | 13 | 2.8 | 2.8 |
| Fremanezumab-Vfrm | 3 | 2.4 | 2.4 |
| Ixekizumab | 9 | 2.3 | 2.3 |
| Elexacaftor, Tezacaftor, And Ivacaftor | 3 | 2.3 | 2.3 |
| Voxelotor | 5 | 2.1 | 2.1 |
| Somatropin | 16 | 2.0 | 2.0 |
| Bimekizumab | 4 | 1.8 | 1.8 |
| Apremilast | 26 | 1.7 | 1.7 |
| Etonogestrel | 7 | 1.4 | 1.4 |
| Dupilumab | 65 | 1.3 | 1.3 |